YD Bio

YD Bio Net Margin

The Net Profit Margin of YD Bio (YDES) as of Oct 16, 2026 is -1,392.61 %. In the previous year, Net Profit Margin was -276.58 % — a change of 403.51% (lower).

Net Margin

-1,392.61 %

YoY

403.51%

Last updated:

Net Profit Margin of YD Bio is 2025 -1,392.61 % . Net Profit Margin of YD Bio was 2024 -276.58 % . It decreases by 403.51% lower compared to the previous year.

YD Bio's net margin stands at -1,392.6%, down from 3.9% several years earlier.

The YD Bio Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2023
3.87 USD
Jan 1, 2024
-276.58 USD
Jan 1, 2025
-1,392.61 USD
The YD Bio Net Margin history
YEARNet MarginYoY
-1,392.61 %+403.51%
-276.58 %-7,241.56%
3.87 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

YD Bio Stock analysis

What does YD Bio do? YD Bio Ltd is a company based in Taipei City, Taiwan, with its headquarters located in Taipei City. The company is set to go public on August 29, 2025, under the ticker symbol YDES and ISIN KYG983011076. YD Bio Ltd focuses on developing innovative solutions in the healthcare sector, particularly in early cancer detection and next-generation cell therapies. The company's core activities include creating non-invasive cancer detection tools for early diagnosis and monitoring, as well as developing ophthalmologic products for dry eye conditions. Additionally, YD Bio Ltd is engaged in exosome-based therapeutics designed to address complex diseases. The company aims to enhance patient outcomes and quality of life through the integration of advanced scientific research with practical, accessible healthcare solutions. YD Bio Ltd operates within the healthcare industry, though specific sector and industry classifications are not provided. The company's website is http://ir.ydesgroup.com/, where further information about its operations and future plans can be found. As a Taiwan-based entity, YD Bio Ltd contributes to the biotechnology and medical innovation landscape in the region. The company's IPO date is scheduled for 2025, indicating its readiness to expand its market presence and potentially scale its operations. YD Bio Ltd's mission centers on pioneering transformative healthcare solutions that improve and extend patient lives. YD Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about YD Bio stock

Net Profit Margin of YD Bio is -1,392.61 % in 2025.

Net Profit Margin of YD Bio changed from -276.58 % to -1,392.61 %, representing a 403.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin YD Bio since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's YD Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — YD Bio

All Key Metrics — YD Bio